Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 3Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Vomiting 1Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Philadelphia Chromosome 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Nausea 1Metastatic Neuroendocrine Prostate Cancer 1Medulloblastoma 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, B-Cell 1Leukemia 1Hematologic Neoplasms 1Ependymoma 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Solid Tumors 1

Interventions

Temozolomide 26Magnetic Resonance Spectroscopy 19Etoposide 14Cyclophosphamide 13Radiotherapy 11Filgrastim 10Bevacizumab 10Carboplatin 9Biopsy 8Cisplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Carmustine 6Radiation 5Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Vincristine 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Erlotinib Hydrochloride 4Azacitidine 4olaparib 3etoposide phosphate 3Surveys and Questionnaires 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × Antiemetics × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡